These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 843215)

  • 21. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCG immunotherapy in previously treated malignant melanoma patients.
    Mujagić H; Kolarić K; Malenica B; Nola P
    Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.
    Golub SH; Forsythe AB; Morton DL
    Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
    Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K
    Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS; Peters M
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intralesion BCG vaccine therapy in cutaneous melanoma metastasis].
    Wolf M; Menzel W
    Dermatol Monatsschr; 1978 Sep; 164(9):671-2. PubMed ID: 710658
    [No Abstract]   [Full Text] [Related]  

  • 32. Granulomas in melanoma patients treated with BCG immunotherapy.
    Hatzitheofilou C; Obenchain DF; Porter DD; Morton DL
    Cancer; 1982 Jan; 49(1):55-60. PubMed ID: 7053820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intrafocal BCG therapy of metastasizing malignant melanoma].
    Kunze J; Lesch R; Plagwitz R; Hagedorn M
    Hautarzt; 1978 Nov; 29(11):597-600. PubMed ID: 721465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
    Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
    Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
    Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L; Schoenfeld D; Regelson W; Colsky J; Mittelman A
    Cancer; 1979 May; 43(5):1630-5. PubMed ID: 376098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunology and cutaneous malignant melanoma.
    Sober AJ
    Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
    [No Abstract]   [Full Text] [Related]  

  • 39. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
    Tan JK; Ho VC
    J Dermatol Surg Oncol; 1993 Nov; 19(11):985-90. PubMed ID: 8245304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications.
    Felix EL; Jessup JM; Cohen MH
    Arch Surg; 1978 Jul; 113(7):893-6. PubMed ID: 678104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.